Bio

Kevin Karl is a Managing Director with Alvarez & Marsal’s Transaction Advisory Group in New York. Mr. Karl specializes in buy-side and sell-side financial due diligence for private equity firms and strategic buyers. He brings fifteen years of transaction experience across manufacturing, distribution, consumer products, and business services. Mr. Karl also has specific expertise in branded and generic pharmaceuticals and life sciences. Most recently, Mr. Karl advised on several sell-side pharmaceutical transactions for private equity firms and corporates, including a manufacturer of respiratory and ophthalmic drugs in the U.S. that was sold to a European-Asian private equity fund and a manufacturer of generic liquid pharmaceuticals in the sale to a partnership formed by a private equity fund and healthcare-focused investment firm. Mr. Karl also performed two reverse due diligence engagements for public biopharmaceutical companies that successfully defended unsolicited takeover offers by another public biopharmaceutical company. Mr. Karl furthered his private equity experience within the Private Equity and Principal Investments Group at the Lehman Brothers estate, which was restructured under Chapter 11. His primary responsibilities included portfolio management for health care venture capital investments, monitoring performance, quarterly valuations, evaluating and executing transactions, restructuring distressed investments, and actively recommending investment alternatives based on risk analysis. Prior to joining A&M, he was a manager with the assurance and business advisory services practice of PricewaterhouseCoopers LLP in New Jersey, where he was an instrumental member of the pharmaceutical industry practice. He performed Sarbanes-Oxley 404 implementation guidance for an SEC registrant with revenues exceeding $35 billion and various consulting roles with Fortune 100 companies. He also served in PricewaterhouseCoopers’ sports industry practice, leading multiple engagements for the NBA and NFL. Prior to joining PricewaterhouseCoopers, Mr. Karl spent two years in the assurance and advisory services group of Arthur Andersen LLP in New York. His most notable achievement included the preparation of a Form S-1 in conjunction with Medco Health Solutions’ initial public offering, which was a spin-off from Merck and valued at over $10 billion. Mr. Karl earned a bachelor’s degree in accounting from Fairfield University, where he was a member of the Alpha Sigma Nu Honor Society. He is a Certified Public Accountant (CPA) licensed in both New York and New Jersey, and a member of the American Institute of Certified Public Accountants (AICPA).